Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 193 clinical trials
INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy or in combination with ruxolitinib in participants with MF who are transfusion-dependent or presenting with symptomatic anemia. This study will consist of 2 parts: dose escalation and …

  • 0 views
  • 01 Apr, 2021
  • 6 locations
Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation

(AML), respectively. The study team hypothesize that the combination of these agents in patients with MPN with an IDH2 mutation will improve the overall clinical response to therapy.

  • 0 views
  • 30 May, 2021
  • 11 locations
PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

This phase I trial studies the side effects and best dose of PLX51107 and how well it works with azacitidine in treating patients with acute myeloid leukemia or myelodysplastic syndrome. PLX51107 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used …

hemolysis
leukemia
cytotoxic agents
potassium
calcium
  • 0 views
  • 24 Jan, 2021
  • 1 location
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Haploidentical Hematopoietic Cell Transplantation

Neoplasms (MPN.

fludarabine
myeloproliferative disorder
cyclophosphamide
graft versus host disease
blast cells
  • 4 views
  • 27 Jan, 2021
A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT

side effects are seen in patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN), Chronic Myelomonocytic Leukemia (CMML), or Myelofibrosis (MF

hemolysis
leukemia
myelodysplastic/myeloproliferative neoplasm
corticosteroid therapy
myelodysplastic syndromes
  • 50 views
  • 25 Jan, 2021
Haplo Peripheral Blood Sct In GVHD Prevention

(MDS), myeloproliferative disorders (MPN), chronic myelomonocytic leukemic (CMML), chemosensitive hodgkin lymphoma (HL), or Non-Hodgkin lymphoma (NHL).who will have a blood stem cell transplantation

hemolysis
renal function test
hodgkin's disease
fludarabine
mycophenolate mofetil
  • 0 views
  • 25 Jan, 2021
Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia High-Risk Myelodysplastic Syndrome or High-Risk Myeloproliferative Neoplasm

syndrome or high-risk myeloproliferative neoplasm. Gemtuzumab ozogamicin is a monoclonal antibody, called gemtuzumab, linked to a chemotherapy drug, called ozogamicin. Gemtuzumab is a form of targeted

leukemia
gemtuzumab
monoclonal antibodies
tumor cells
monoclonal protein
  • 5 views
  • 27 May, 2021
  • 1 location
Azacitidine Venetoclax and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

This phase I/II trial studies the best dose of venetoclax when given together with azacitidine and pevonedistat and to see how well it works in treating patients with newly diagnosed acute myeloid leukemia. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer …

dysplasia
mds/mpn-rs-t
essential thrombocythemia
chronic myelomonocytic leukemia
tumor cells
  • 40 views
  • 18 Mar, 2021
  • 1 location
Azacitidine Venetoclax and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia Chronic Myelomonocytic Leukemia or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm

positive acute myeloid leukemia, chronic myelomonocytic leukemia, or high-risk myelodysplastic syndrome/myeloproliferative neoplasm that has come back (recurrent) or has not responded to treatment

  • 8 views
  • 28 Mar, 2021
  • 1 location
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Participants With IDH1 Mutated Hematologic Malignancies

This phase Ib/II trial studies the side effects and best dose of venetoclax and how well it works when given together with ivosidenib with or without azacitidine, in treating participants with IDH1-mutated hematologic malignancies. Venetoclax and ivosidenib may stop the growth of cancer cells by blocking some of the enzymes …

leukemia
refractory acute myeloid leukemia (aml)
ivosidenib
venetoclax
cancer
  • 39 views
  • 29 May, 2021
  • 6 locations